"HIV Protease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Enzyme of the human immunodeficiency virus that is required for post-translational cleavage of gag and gag-pol precursor polyproteins into functional products needed for viral assembly. HIV protease is an aspartic protease encoded by the amino terminus of the pol gene.
| Descriptor ID |
D016333
|
| MeSH Number(s) |
D08.811.277.656.074.500.340 D08.811.277.656.300.048.340 D12.776.964.775.375.545.750
|
| Concept/Terms |
HIV Protease- HIV Protease
- Protease, HIV
- p16 pol gene product, HIV
- p16 protease, HIV
- HIV p16 protease
- HIV Proteinase
- HTLV-III Protease
- HTLV III Protease
- Protease, HTLV-III
|
Below are MeSH descriptors whose meaning is more general than "HIV Protease".
Below are MeSH descriptors whose meaning is more specific than "HIV Protease".
This graph shows the total number of publications written about "HIV Protease" by people in this website by year, and whether "HIV Protease" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2010 | 1 | 0 | 1 |
| 2012 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 7 | 6 | 13 |
| 2018 | 8 | 3 | 11 |
| 2019 | 4 | 2 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "HIV Protease" by people in Profiles.
-
Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study. J Biomol Struct Dyn. 2021 09; 39(15):5368-5375.
-
Computational Determination of Potential Inhibitors of SARS-CoV-2 Main Protease. J Chem Inf Model. 2020 12 28; 60(12):5771-5780.
-
Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies. ChemMedChem. 2019 11 06; 14(21):1863-1872.
-
Potent HIV-1 protease inhibitors incorporating squaramide-derived P2 ligands: Design, synthesis, and biological evaluation. Bioorg Med Chem Lett. 2019 09 15; 29(18):2565-2570.
-
New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations. J Antimicrob Chemother. 2019 07 01; 74(7):2019-2023.
-
HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen. J Antimicrob Chemother. 2019 06 01; 74(6):1679-1692.
-
Partial pol Sequences from Drug Naive HIV-2 Infected Individuals from Maharashtra, India. AIDS Res Hum Retroviruses. 2019 05; 35(5):505-508.
-
Characterizing the structural variability of HIV-2 protease upon the binding of diverse ligands using a structural alphabet approach. J Biomol Struct Dyn. 2019 10; 37(17):4658-4670.
-
Ultra-deep sequencing improves the detection of drug resistance in cellular DNA from HIV-infected patients on ART with suppressed viraemia. J Antimicrob Chemother. 2018 11 01; 73(11):3122-3128.
-
Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands. Eur J Med Chem. 2018 Dec 05; 160:171-182.